American International Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-13,757
| Closed | -$1.4M | – | 3065 |
|
|
2023
Q2 | $1.4M | Buy |
13,757
+413
| +3% | +$39.1K | 0.01% | 1082 |
|
|
2023
Q1 | $1.21M | Buy |
13,344
+265
| +2% | +$15.6K | 0.01% | 1143 |
|
|
2022
Q4 | $497K | Sell |
13,079
-47
| -0.4% | -$1.62K | ﹤0.01% | 1596 |
|
|
2022
Q3 | $330K | Buy |
13,126
+185
| +1% | +$5.13K | ﹤0.01% | 1841 |
|
|
2022
Q2 | $393K | Sell |
12,941
-690
| -5% | -$20.6K | ﹤0.01% | 1770 |
|
|
2022
Q1 | $447K | Sell |
13,631
-959
| -7% | -$28.5K | ﹤0.01% | 1780 |
|
|
2021
Q4 | $385K | Sell |
14,590
-437
| -3% | -$33.8K | ﹤0.01% | 1980 |
|
|
2021
Q3 | $1.51M | Sell |
15,027
-357
| -2% | -$41.8K | 0.01% | 1188 |
|
|
2021
Q2 | $2.18K | Buy |
15,384
+14,826
| +2,657% | +$1.67M | 0.01% | 1084 |
|
|
2021
Q1 | $56 | Sell |
558
-15
| -3% | -$1.75K | ﹤0.01% | 2958 |
|
|
2020
Q4 | $71 | Sell |
573
-23
| -4% | -$3.02K | ﹤0.01% | 2831 |
|
|
2020
Q3 | $58K | Sell |
596
-17
| -3% | -$2.12K | ﹤0.01% | 2829 |
|
|
2020
Q2 | $96K | Sell |
613
-12,801
| -95% | -$1.95M | ﹤0.01% | 2559 |
|
|
2020
Q1 | $1.94M | Sell |
13,414
-591
| -4% | -$114K | 0.01% | 892 |
|
|
2019
Q4 | $2.86M | Buy |
14,005
+1,311
| +10% | +$239K | 0.01% | 903 |
|
|
2019
Q3 | $1.02M | Sell |
12,694
-88
| -0.7% | -$7.47K | ﹤0.01% | 1279 |
|
|
2019
Q2 | $1.21M | Buy |
12,782
+730
| +6% | +$63K | ﹤0.01% | 1222 |
|
|
2019
Q1 | $1.03M | Sell |
12,052
-258
| -2% | -$21.4K | ﹤0.01% | 1300 |
|
|
2018
Q4 | $691K | Sell |
12,310
-94
| -0.8% | -$5.74K | ﹤0.01% | 1485 |
|
|
2018
Q3 | $1.01M | Buy |
12,404
+2,044
| +20% | +$144K | ﹤0.01% | 1435 |
|
|
2018
Q2 | $362K | Buy |
10,360
+3,128
| +43% | +$95.3K | ﹤0.01% | 2027 |
|
|
2018
Q1 | $148K | Sell |
7,232
-390
| -5% | -$10K | ﹤0.01% | 2443 |
|
|
2017
Q4 | $216K | Buy |
7,622
+94
| +1% | +$2.62K | ﹤0.01% | 2278 |
|
|
2017
Q3 | $234K | Buy |
7,528
+2,247
| +43% | +$67.6K | ﹤0.01% | 2208 |
|
|
2017
Q2 | $167K | Buy |
5,281
+1,751
| +50% | +$43K | ﹤0.01% | 2390 |
|
|
2017
Q1 | $80K | Buy |
3,530
+260
| +8% | +$6.42K | ﹤0.01% | 2699 |
|
|
2016
Q4 | $71K | Sell |
3,270
-9
| -0.3% | -$228 | ﹤0.01% | 2762 |
|
|
2016
Q3 | $86.4K | Buy |
3,279
+5
| +0.2% | +$99 | ﹤0.01% | 2686 |
|
|
2016
Q2 | $64.7K | Buy |
+3,274
| New | +$63.6K | ﹤0.01% | 2865 |
|
Other funds holding RETA
American International Group's RETA Position: Q3 2023 in Review
American International Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 13,757 shares — an estimated $1.4M sold.
American International Group first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $2.86M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- American International Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- American International Group sold 13,757 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.4M.
- American International Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- American International Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.86M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on American International Group's 13F filing for Q3 2023, filed 13 Nov 2023.